Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IG202
- Development stage
- Preclinical
- Lead developer
- Ingenium Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Parenteral
01
Overview
IG202 is a preclinical-stage therapeutic candidate being developed by Ingenium Therapeutics. It is built on the company's proprietary Target Immune Stimulator (TIS) platform, which is designed to deliver two therapeutic payloads directly to tumors to stimulate a localized immune response. The dual-payload TIS platform utilizes an antibody-linker-two-payload architecture. The payloads consist of an IL-21/15 fusion cytokine and TN13, a peptide-based p38 inhibitor that regulates the tumor microenvironment (TME) and protects natural killer (NK) cells from TGF-β-mediated immunosuppression. IG202 is intended for the treatment of slow-dividing and treatment-resistant cancers, including solid tumors.
Beyond the preview
Go deeper on IG202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IG202.